Literature DB >> 17994243

[Clinical risk-adapted therapies in systemic sclerosis].

G Riemekasten1, D Dragun.   

Abstract

Systemic sclerosis is a challenging disease in terms of early risk assessment and the implications for therapy. The current article draws on a literature analysis and on personal experience of over 450 patients with systemic sclerosis and related illnesses, describing an attempt at a risk-adapted treatment strategy for patients with systemic sclerosis, and is intended to be used as a discussion paper. A major point of emphasis is on novel therapeutic options for patients who are refractory to current treatment strategies and who are at a high risk of serious complications or a limited prognosis. The paper also highlights possible future treatment options, including vasoactive, cellular and immune suppressant treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994243     DOI: 10.1007/s00393-007-0225-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  31 in total

Review 1.  Scleroderma renal crisis: new insights and developments.

Authors:  Elisa Y Rhew; Walter G Barr
Journal:  Curr Rheumatol Rep       Date:  2004-04       Impact factor: 4.592

2.  Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis.

Authors:  H U Scherer; G-R Burmester; G Riemekasten
Journal:  Ann Rheum Dis       Date:  2006-09       Impact factor: 19.103

3.  Antimalarial agents: closing the gate on Toll-like receptors?

Authors:  Robert Lafyatis; Michael York; Ann Marshak-Rothstein
Journal:  Arthritis Rheum       Date:  2006-10

4.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.

Authors:  Silvia Svegliati Baroni; Mariarosaria Santillo; Federica Bevilacqua; Michele Luchetti; Tatiana Spadoni; Matteo Mancini; Paolo Fraticelli; Paola Sambo; Ada Funaro; Andrius Kazlauskas; Enrico V Avvedimento; Armando Gabrielli
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

5.  B cell infiltration in systemic sclerosis-associated interstitial lung disease.

Authors:  Robert Lafyatis; Carl O'Hara; Carol A Feghali-Bostwick; Eric Matteson
Journal:  Arthritis Rheum       Date:  2007-09

6.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

7.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Authors:  Jörg H W Distler; Astrid Jüngel; Lars C Huber; Ursula Schulze-Horsel; Jochen Zwerina; Renate E Gay; Beat A Michel; Thomas Hauser; Georg Schett; Steffen Gay; Oliver Distler
Journal:  Arthritis Rheum       Date:  2007-01

Review 8.  Adult stem cells in the treatment of autoimmune diseases.

Authors:  J M van Laar; A Tyndall
Journal:  Rheumatology (Oxford)       Date:  2006-06-15       Impact factor: 7.580

9.  Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

Authors:  Paul J DeMarco; Michael H Weisman; James R Seibold; Daniel E Furst; Weng Kee Wong; Eric L Hurwitz; Maureen Mayes; Barbara White; Fredrick Wigley; Walter Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Philip J Clements
Journal:  Arthritis Rheum       Date:  2002-11

10.  A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis.

Authors:  O Nadashkevich; P Davis; M Fritzler; W Kovalenko
Journal:  Clin Rheumatol       Date:  2005-10-14       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.